DENTSPLY SIRONA Inc. (XRAY) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary presents a mixed outlook: while there are positive elements such as strategic investments, operational improvements, and a favorable agreement with Patterson, there are also concerns about declining sales and unclear management responses on key issues like free cash flow and new product launches. The Q&A section reveals optimism for future growth but also highlights uncertainties, particularly with regulatory approvals and market penetration strategies. Given the absence of a market cap, the predicted stock movement is neutral, reflecting both potential growth and existing challenges.
Key Financial Performance
Q4 2025 Revenue $961 million, representing a reported sales increase of 6.2% and constant currency growth of 2.5%. The increase was against a lower prior year comp that included a onetime Byte customer refund and distributor pre-buys related to ERP implementation. Foreign currency positively impacted sales by 370 basis points.
Adjusted EBITDA Margins (Q4 2025) Declined 10 basis points to 14.1%, driven by a 300 basis point decline in gross profit due to lower volume, change in sales mix, and tariff impacts. Tariffs had an approximately $15 million impact to gross profit.
Adjusted EPS (Q4 2025) $0.27, up $0.01 or 4.9% from the prior year. The increase was partially offset by a $144 million noncash net of tax charge related to the impairment of goodwill and other intangible assets.
Operating Cash Flow (Q4 2025) $101 million, with $60 million of free cash flow generated.
Net Debt-to-EBITDA Ratio (Q4 2025) 3.0, consistent with the prior quarter.
Dividends Paid (Q4 2025) $32 million, bringing total dividends returned to shareholders to $128 million for the full year of 2025.
CTS Segment Sales (Q4 2025) Constant currency sales declined 1.9% due to lower sales in CAD/CAM in Rest of World and Europe, partially offset by high single-digit growth in the U.S. across equipment, instruments, and CAD/CAM.
EDS Segment Sales (Q4 2025) Sales on a constant currency basis increased 4%, led by preventative products which grew 17% with strong performance in the U.S. and Rest of World.
OIS Segment Sales (Q4 2025) Sales in constant currency increased 6.9%, driven by the issuance of customer refunds for Byte in Q4 2024. IPS declined high single digits due to lower implant volumes across all regions.
Wellspect HealthCare Sales (Q4 2025) Constant currency sales increased 1.9%, including 15% growth in the U.S. and continued strength in Rest of World, partially offset by Europe.
Full Year 2025 Revenue $3.68 billion, representing a reported sales decline of 3% and a 4.3% decline on a constant currency basis. Byte negatively impacted constant currency by 1.9%.
Adjusted EBITDA Margins (Full Year 2025) Expanded 150 basis points to 18.1%, primarily driven by lower SG&A, partially offset by a decline in gross profit due to geographical mix and tariffs. Tariffs represented a $23 million headwind to gross profit.
Adjusted EPS (Full Year 2025) $1.60, down $0.07 or negative 4.6% year-on-year, driven by a higher tax rate. Includes approximately $0.13 of income from Byte, which will not recur in 2026.
Operating Cash Flow (Full Year 2025) $235 million, with $104 million of free cash flow generated.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Wellspect Surity female external catheter: Launched a new noninvasive solution designed to support women living with severe urinary incontinence.
CEREC on DS Core: Enhanced workflow efficiency by integrating CEREC onto DS Core.
EDS and IPS portfolios: Introduced new products to enhance offerings.
U.S. market: Reorganized and unified commercial teams to better compete, hired new leadership, and expanded agreements with key partners like Benco, Patterson, Burkhart, and A-dec.
China market: Faced challenges with implant volumes due to shifting buying behavior in anticipation of volume-based procurement in 2026.
Europe market: Achieved 11% growth in value implants and 15% growth in SureSmile clear aligners.
Restructuring program: Initiated a program to streamline functions, improve efficiency, and unlock approximately $120 million annually for reinvestment.
Manufacturing and distribution: Consolidating resources, standardizing packaging, and implementing advanced planning to reduce costs and improve scalability.
Return to Growth action plan: Focused on customer-centricity, sustainable growth, performance empowerment, organizational scaling, and financial strength.
Capital allocation changes: Eliminated dividend to reallocate funds for debt retirement and share repurchases.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Tariffs: Tariffs had a significant impact on gross profit, with a $15 million impact in Q4 2025 and $23 million for the full year. This represents a headwind to profitability and financial performance.
Volume Declines: Lower volumes in CAD/CAM and implants across all regions negatively impacted sales and financial performance in 2025.
Competitive Pressures: Competitive pressures contributed to volume declines and a $144 million noncash impairment charge related to goodwill and intangible assets in the CTS and OIS segments.
China Market Dynamics: Implant volumes in China declined due to shifting buying behavior in anticipation of the second phase of volume-based procurement in 2026, leading to a double-digit decline in the second half of 2025.
U.S. Market Challenges: The U.S. market faced challenges, including a 10% decline in SureSmile sales and low distributor inventory levels, impacting growth and market penetration.
Restructuring Costs: The restructuring program to streamline functions and improve efficiency is expected to incur $55 million to $65 million in nonrecurring charges, creating short-term financial strain.
Dividend Elimination: The elimination of the dividend may impact shareholder sentiment and reflects a shift in capital allocation priorities.
Byte Business Wind-Down: The wind-down of the Byte business will result in a headwind to earnings in 2026, as income from Byte will no longer recur.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2026 Financial Guidance: Net sales expected to be in the range of $3.5 billion to $3.6 billion, reflecting a negative 3% to negative 1% operational growth. Adjusted earnings per share projected to be between $1.40 and $1.50. Positive sequential sales momentum anticipated in the second half of the year.
Restructuring Program: Expected to unlock approximately $120 million annually across the P&L, which will be reinvested in the Return to Growth action plan. Approximately $55 million to $65 million in nonrecurring charges anticipated, mostly expensed and paid in cash in 2026 and 2027.
R&D Investment: Increasing R&D investment by double digits in 2026 to accelerate innovation in EDS, implants, and orthodontics, as well as advance connected dentistry.
Capital Allocation Changes: Eliminating dividend to reallocate funds toward debt retirement and share repurchases. Committed to maintaining investment-grade credit metrics and prioritizing debt reduction.
Operational Changes: Initiating a restructuring program to streamline functions, improve efficiency, and support a more competitive cost structure. Consolidating resources, standardizing packaging, and implementing advanced planning and forecasting capabilities to reduce product costs and improve working capital.
Market Focus: Restoring the health of the U.S. business is a top priority, with a comprehensive plan to reignite growth and strengthen the commercial foundation. Focus on implants and orthodontics to leverage best-in-class products and modernize software.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividends paid in Q4 2025: $32 million
Total dividends returned in 2025: $128 million
Dividend policy change: Eliminated dividend to reallocate funds to debt retirement and share repurchases
Share repurchase plan: Funds from eliminated dividend will be reallocated to share repurchases over time as part of a new capital allocation strategy
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:You've talked about the dividend elimination freeing up $128 million annually for capital deployment. Can you discuss the optimal mix of debt retirement and share repurchases and at what share price levels do you view the stock as compelling?
A:The company plans to prioritize debt retirement initially to avoid moving below investment grade. Management views the current stock price as attractive and aims to buy back shares later in the year if the restructuring plan progresses as expected. There is no structured cadence for share repurchases, but management sees the current price as a bargain.
Q:What is the estimated revenue headwind from the new dealer inventory model, and when should we expect this impact in 2026?
A:The transition to a drop-ship model is expected to result in a revenue headwind of approximately $30 million. The inventory sell-through by vendors is anticipated to occur in the first half of the year, with the full drop-ship model implemented by the fourth quarter.
Q:How do you think about the timing around the recent expansion with Patterson, Benco, and Burkhart? Is any of that benefit included in the guidance?
A:The benefit from these expansions is not a major part of the guidance. The company expects activity in the first and second quarters to bear fruit in the late third quarter or early fourth quarter. The impact is expected to be more significant in the second half of the year.
Q:Regarding the EPS guide of $1.40 to $1.50, should we think about 2026 being the peak year for investments, or will they ramp up over the next couple of years?
A:2026 is expected to be a strong year for investments, with similar levels in 2027. Management aims for the business to become self-funding by then, with top-line growth outpacing EPS growth.
Q:How do you think about the cadence of R&D spend and the development cycles for new products?
A:R&D spend is increasing by double digits to accelerate development in DS core, EDS, and ortho. Some projects will launch sooner due to accelerated funding, but others require FDA approval. The company is focusing on both new developments and accelerating delayed projects.
Q:Is the reorganization of the commercial team complete, and when should we expect to see benefits?
A:The reorganization is complete, and the new structure is active as of March and April. Benefits are expected to start materializing over the next two to three quarters.
Q:How should we think about the pacing of sales improvement as the Return-to-Growth action plan is implemented?
A:Management expects consistent velocity in Q1 and Q2, with noticeable changes in Q3. The U.S. business is expected to show positive growth, albeit small, in Q4, setting the stage for 2027.
Q:How are you thinking about SG&A and R&D expenses as a percentage of revenue?
A:SG&A expenses are expected to grow at half the rate of sales growth. R&D expenses are projected to increase from 4% to around 5% of revenue, with a potential target of 6% in the future.
Q:Has there been any thought to adjusting price points for competitive products, or is the focus on innovation?
A:The focus is on driving innovation and maintaining a premium position in the market. Management does not plan to lower price points but aims to offer differentiated and meaningful products.
Q:Which revenue segments are poised for the biggest year-over-year improvements in 2026?
A:CTS is expected to be the first mover, followed by EDS. Implants are a focus area for improvement, while ortho will take longer due to software modernization efforts.
Q:What is the company's strategy for penetrating the DSO market?
A:The company is exploring plans to partner with DSOs by offering a full suite of products and disposables. However, meaningful moves in this area are not expected until 2027 or 2028.
Q:Can the U.S. business achieve positive growth in Q4 without a market turn?
A:Yes, the company believes it can achieve positive growth in Q4 regardless of market conditions by improving execution and leveraging its existing capabilities.
Q:What is the expected impact of increased R&D spend on new product launches?
A:The increased R&D spend will not meaningfully pull forward new product launches into 2026. The focus is on closing the gap for launches in 2027 and 2028, subject to FDA approvals.
Q:Are there any noticeable gaps in the portfolio that need to be addressed?
A:Management does not see significant gaps in the portfolio. The focus is on strengthening brands, clinical education, and digitization rather than launching new products.
Q:Is hiring competitive reps a lever the company can pull this year?
A:The company may consider hiring competitive reps later in the year, but the priority is to get existing teams formed and functioning first.
Q:How is the company prioritizing its focus on China?
A:The company is prioritizing the U.S. and EMEA markets first. While China is of strategic interest, it currently represents a low single-digit percentage of total sales. Plans for China are still under evaluation.
Q:What are the headwinds and tailwinds for free cash flow this year?
A:The company does not provide specific free cash flow guidance but aims to improve it through working capital exercises. The dividend elimination will free up $130 million for debt retirement and share repurchases.
Q:What steps have been taken to turn around the implants business?
A:The company has created a focused sales force, expanded clinical education, and accelerated R&D for implants. Branding strategy and integration with other products are still being finalized.
Q:What is the impact of the new Patterson agreement on 2026?
A:The new contract with Patterson is expected to be favorable and provide a meaningful lift in 2026. The agreement includes terms that benefit both parties and enhance training and market penetration.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the timing of share repurchases, the exact cadence of R&D investments, and the free cash flow figure for 2026. Additionally, they refrained from commenting on new product launches pending FDA approvals and did not elaborate on plans for the DSO market or China beyond general statements.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Byte income
Byte increase
Byte noncash
CAM implant
CEO Interim
CTS OIS
China Europe
DENTSPLY SIRONA
Director afternoon
EDS World
EDS segment
Europe Slide
Europe SureSmile
Europe Wellspect
Europe segment
Financial Officer
Sales currency
Tariffs
World Europe
World product
action plan
afternoon DENTSPLY
currency basis
currency sale
customer refund
digit decline
dividend
flow cash
impact
impairment
implant China
income Byte
mix tariff
priority
product category
refund distributor
sale basis
XRAY Transcript
DENTSPLY SIRONA Inc. (XRAY) Presents at Stifel Jaws & Paws Conference 2026 Transcript
Neutral5-27
DENTSPLY SIRONA Inc. (XRAY) Q1 2026 Earnings Call Transcript
Unknown5-5
The earnings call reveals mixed signals: strong product sales and EMEA growth, but weak guidance and margin contraction. The restructuring plan shows potential, but its benefits are long-term. Eliminating dividends for debt reduction and share repurchases is neutral. Unclear management responses in Q&A raise concerns. These factors balance out, suggesting a neutral stock price movement in the short term.
DENTSPLY SIRONA Inc. (XRAY) Presents at Leerink Global Healthcare Conference 2026 Transcript
Neutral3-10
DENTSPLY SIRONA Inc. (XRAY) Q4 2025 Earnings Call Transcript
Unknown2-27
The earnings call summary presents a mixed outlook: while there are positive elements such as strategic investments, operational improvements, and a favorable agreement with Patterson, there are also concerns about declining sales and unclear management responses on key issues like free cash flow and new product launches. The Q&A section reveals optimism for future growth but also highlights uncertainties, particularly with regulatory approvals and market penetration strategies. Given the absence of a market cap, the predicted stock movement is neutral, reflecting both potential growth and existing challenges.
XRAY Slides
Dentsply Sirona Q4 2025 slides: revenue beats amid restructuring push2026-02-26
Dentsply Sirona Q3 2025 slides: Sales decline despite margin gains, stock falls 12%2025-11-06
Dentsply Sirona Q2 2025 slides: Sales decline offset by margin expansion under new leadership2025-08-07
Dentsply Sirona Q1 2025 slides: Margin expansion offsets continued sales decline2025-05-08
XRAY Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
